# Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

> **NCT03859739** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 21 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** MK-8558

## Key facts

- **NCT ID:** NCT03859739
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-26
- **Primary completion:** 2020-05-29
- **Final completion:** 2020-05-29
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03859739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03859739, "Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03859739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*